Hair Inhibitor - Vaniqa Cream

Vaniqa is a prescription-only topical cream that has been FDA-approved in July 2000 for reducing and inhibiting the growth of unwanted facial hair for women. Vaniqa contains 13.9% active ingredient eflornithine, which works by blocking the action of an enzyme called ornithine decarboxylase. This is an enzyme found in hair follicles and is needed for hair to grow. By blocking this enzyme, eflornithine slows down hair growth.

Vaniqa is applied twice a day and must be continued for as long as inhibition of hair growth is desired. Noticeable results are usually observed after 4-8 weeks because hair grows in cycles and you are treating the hair that is not yet growing, not the hair that is currently on your face. This effect slows hair growth and may also make the hair finer and lighter but it does not remove hair or cause the hair to fall out. If you stop taking Vaniqa, your hair may come back to previous levels within two months after stopping. If no improvement is seen after four months then treatment should be stopped.

Almost 600 patients were studied who routinely had to remove facial hair at least twice weekly and had more than 5 hairs per square centimeter of skin. The re-growth of hair was evaluated 48 hours after patients shaved before, during, and at the end of treatment. The patients received either Vaniqa cream or a placebo cream twice daily for 24 weeks. By the end of 24 weeks of treatment, 70% of Vaniqa-treated patients had at least some reduction in the rate of hair growth compared with 41% of placebo-treated patients. Moreover, 35% of Vaniqa-treated patients had a marked reduction in the rate of growth (only minimal darkening of facial skin due to re-growth of hair) compared to 9% of placebo-treated patients.

Hair Inhibitor - Vaniqa Cream

Side Effects

Reported side effects that may go away during treatment, it may cause temporary redness, rash , burning, stinging, or tingling, especially if it is applied to broken or irritated skin. If irritation develops, reduce the application of eflornithine topical to once a day. If irritation continues, stop using it and contact your doctor.

Acne : 10.8-21.4%
Pseudofolliculitis Barbae : 4.9-16.3%
Stinging Skin : 4.1-7.9%
Headache : 3.8-5%
Burning Skin : 3.5-4.3%
Pruritus (Intense Itching) : 3.1-4%
Tingling Skin : 2.2-3.6%
Dry Skin : 1.8-3.3%
Rash : 1.5-2.8%
Alopecia (Hair Loss) : 1.5-2.5%
Erythema (abnormal skin redness from dilation of blood vessels) : 1.3-2.5%
Dyspepsia (Indigestion) : 1.9-2.5%
Dizziness : 1.3-1.5%
Skin Irritation : 1-1.8%
Anorexia : 0.7-2%
Nausea : 0.5-1%
Folliculitis (Inflammation Of A Hair Follicle) : 0.5-1%
Facial Edema Or Swelling : 0.3-3%
Ingrown Hair : 0.3-2%
Asthenia (Abnormal Loss Of Strength) : 0-1%
Bleeding Skin, Cheilitis, Contact Dermatitis, Herpes Simplex, Numbness, Rosacea : Less Than 1%

Vaniqa Should Not Be Ued

  • By men. It has not been tested on males.
  • Pregnant or Nursing. Vaniqa has not been tested to see if it causes birth defects and miscarriages in humans.
  • By females under age 12.
  • Anywhere except on the face and chin.
  • In the eyes, nose, mouth, or vagina.
  • If you have severe acne or broken skin.
Best Clinics